BSE - Delayed Quote INR

Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)

1,744.85

-21.35

(-1.21%)

At close: May 9 at 3:29:35 PM GMT+5:30

Update: Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday

(Adds Checkpoint's stock move in the headline and first paragraph. Adds Fortress Biotech's stock mov

PREMIUM
MT Newswires last month

CKPT

SUNPHARMA.NS

FBIO
India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details

On Sunday, India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted oncology company Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) for an upfront cash payment of $4.10/share. In December, the FDA approved Checkpoint Therapeutics’ Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Unloxcyt is the first and only programmed death

Benzinga last month

CKPT

SUNPHARMA.NS
Sun Pharma agrees to acquire Checkpoint Therapeutics

Stockholders of Checkpoint are set to obtain an upfront cash payment of $4.10 per share of common stock.

Pharmaceutical Technology last month

CKPT

SUNPHARMA.NS
India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln

Investing.com-- Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NSE:SUN) said on Monday that it will buy Checkpoint Therapeutics Inc (NASDAQ:CKPT)- a Nasdaq-listed immunotherapy and oncology firm- for about $355 million.

Investing.com 2 months ago

CKPT

SUNPHARMA.NS
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million

The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations. Last year, it signed a licensing agreement with Italian-Swiss firm Philogen for its anti-cancer drug Fibromun. Monday's transaction, which is expected to be completed in the second quarter of 2025, will add UNLOXCYT, a U.S. FDA-approved treatment for advanced skin cancer, to Sun Pharma's global franchise.

Reuters 2 months ago

CKPT

SUNPHARMA.NS
India flags quality issues with some widely used antacids and paracetamol

BENGALURU (Reuters) -India's drug regulator has found more than 50 drugs, including some batches of widely used antacids and paracetamol, to be substandard or fake, according to government documents. The regulator, Central Drugs Standard Control Organisation, releases a monthly list of substandard or fake medicines sold in the country after routine tests across the country by multiple agencies. The regulator found some drugs as "not of standard quality", including a batch each of Alkem Laboratories' popular antacid Pan-D, Hetero's anti-infective Cepodem and Shelcal, a vitamin and calcium tablet brand made by privately-owned Pure & Cure Healthcare, and several antibiotics, according to the lists for August.

Reuters 7 months ago

SUNPHARMA.NS
Sun Pharma and Moebius gain FDA fast track for osteoarthritis drug

MM-II reduces joint friction and wear, thereby alleviating pain.

Pharmaceutical Technology 7 months ago

SUNPHARMA.NS
India stocks higher at close of trade; Nifty 50 up 0.05%

Investing.com – India stocks were higher after the close on Friday, as gains in the Auto, IT and Capital Goods sectors led shares higher.

Investing.com 8 months ago

SUNPHARMA.NS
Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.

Strategic equity investment of $15 M to support completion of Pharmazz's pivotal Phase 3 study for Sovateltide to treat patients with acute cerebral ischemic strokeExpansion of the exclusive license agreement with Sun Pharma for marketing and distribution of Sovateltide in India to certain additional Emerging Market countries WILLOWBROOK, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz” or the “Company”), a biopharmaceutical company focused on developing and commercializing nov

GlobeNewswire 8 months ago

SUNPHARMA.NS

SUNPHARMA.BO
-1.21%
FDA approves Sun Pharma’s JAK inhibitor for alopecia

The FDA approval is based on data gathered from two Phase III studies where over 30% of the patients gained 80% or more coverage of scalp hair.

Pharmaceutical Technology 9 months ago

SUNPHARMA.NS
Sun Pharma’s Phase I GL0034 study shows weight loss efficacy and lipid reduction

Sun Pharma says GL0034’s additional ability to lower lipid profiles may set it apart from other weight loss treatments.

Clinical Trials Arena 10 months ago

SUNPHARMA.NS
Philogen and Sun Pharma seek EMA approval for melanoma therapy

In a Phase III trial, Nidlegy demonstrated to significantly reduce the relapse or death risk by 41% versus control.

Pharmaceutical Technology 10 months ago

SUNPHARMA.NS

Performance Overview

Return	SUNPHARMA.BO	S&P BSE SENSEX (^BSESN)
YTD	-6.85%	+1.68%
1-Year	+17.92%	+9.74%
3-Year	+102.19%	+45.87%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)

Update: Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday

India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details

Sun Pharma agrees to acquire Checkpoint Therapeutics

India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln

India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million

India flags quality issues with some widely used antacids and paracetamol

Sun Pharma and Moebius gain FDA fast track for osteoarthritis drug

India stocks higher at close of trade; Nifty 50 up 0.05%

Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.

FDA approves Sun Pharma’s JAK inhibitor for alopecia

Sun Pharma’s Phase I GL0034 study shows weight loss efficacy and lipid reduction

Philogen and Sun Pharma seek EMA approval for melanoma therapy

Performance Overview